Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Guelph

$17,500.00

Identification of novel dendritic cell-activating secretomes to generate anti-tumour immunity in Glioblastoma.

FY 2022-23

Summary
The immune system is a powerful ally in fighting cancer. A subset of immune cells, called antigen-presenting cells, can ingest parts of the tumor, and display it to a group of white blood cells called T-cells. The T-cells that recognize the tumor fragment, otherwise known as a tumor antigen, become activated to identify and eliminate cancer cells expressing the target antigen. However, certain brain cancers, like Glioblastoma, can hide from the immune system. As a result, patients with Glioblastoma tend to have poor survival chances after immunotherapy since the tumor microenvironment is highly suppressive for the development and trafficking of anticancer T-cells into the tumor. We identified certain types of cancer cell death release molecules to activate a strong anticancer immunity. We hypothesize that different types of cancer cell death release varying amounts and types of pro-inflammatory molecules to potentiate tumor antigen presentation for generating T cell-mediated anticancer effects. In my previous research, I created model systems to activate 3 types of Glioblastoma cell death. My MSc research aims to (1) comprehensively define the types of pro-inflammatory molecules released following 3 types of Glioblastoma cell death and (2) determine the role of inflammatory molecules in the activation of antigen-presenting cells to present antigens to T cells. The findings of these studies are crucial to discover new pro-inflammatory molecules that can stimulate antigen presentation and T cell activation. The knowledge gained will be foundational to developing new treatments for Glioblastoma immunotherapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486042
Name
Verburg Shayla G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of novel dendritic cell-activating secretomes to generate anti-tumour immunity in Glioblastoma.
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigen Processing And Presentation; Cold Tumor; Cytotoxic T-Cell Infiltration; Dendritic Cell Co-Culture; Dendritic Cell Vaccine; Glioblastoma Immunotherapy; Mass Spectrometry; Programmed Cell Death; Rna Sequencing; Secretome Analysis
Abstract
The immune system is a powerful ally in fighting cancer. A subset of immune cells, called antigen-presenting cells, can ingest parts of the tumor, and display it to a group of white blood cells called T-cells. The T-cells that recognize the tumor fragment, otherwise known as a tumor antigen, become activated to identify and eliminate cancer cells expressing the target antigen. However, certain brain cancers, like Glioblastoma, can hide from the immune system. As a result, patients with Glioblastoma tend to have poor survival chances after immunotherapy since the tumor microenvironment is highly suppressive for the development and trafficking of anticancer T-cells into the tumor. We identified certain types of cancer cell death release molecules to activate a strong anticancer immunity. We hypothesize that different types of cancer cell death release varying amounts and types of pro-inflammatory molecules to potentiate tumor antigen presentation for generating T cell-mediated anticancer effects. In my previous research, I created model systems to activate 3 types of Glioblastoma cell death. My MSc research aims to (1) comprehensively define the types of pro-inflammatory molecules released following 3 types of Glioblastoma cell death and (2) determine the role of inflammatory molecules in the activation of antigen-presenting cells to present antigens to T cells. The findings of these studies are crucial to discover new pro-inflammatory molecules that can stimulate antigen presentation and T cell activation. The knowledge gained will be foundational to developing new treatments for Glioblastoma immunotherapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Verburg, Shayla G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~